Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics
CKPT Price/Volume Stats
| Current price | $1.46 | 52-week high | $3.62 |
| Prev. close | $1.60 | 52-week low | $1.30 |
| Day low | $1.45 | Volume | 763,600 |
| Day high | $1.68 | Avg. volume | 545,543 |
| 50-day MA | $1.95 | Dividend yield | N/A |
| 200-day MA | $2.12 | Market Cap | 52.10M |
CKPT Stock Price Chart Interactive Chart >
Checkpoint Therapeutics, Inc. (CKPT) Company Bio
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Latest CKPT News From Around the Web
Below are the latest news stories about CHECKPOINT THERAPEUTICS INC that investors may wish to consider to help them evaluate CKPT as an investment opportunity.
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit OutlookWe feel now is a pretty good time to analyse Checkpoint Therapeutics, Inc.'s ( NASDAQ:CKPT ) business as it appears the... |
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapyCheckpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. Checkpoint said the FDA did not state any concerns about the data or safety on the drug in its so-called complete response letter. |
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party ManufacturerFDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimabWALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic license application (“BLA”) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma |
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023Some of the most explosive opportunities can be found in biotech stocks. |
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent IssuanceUpcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505) covering a method of treating various cancers, including cutaneous squamous cell carcinoma (“cSCC |
CKPT Price Returns
| 1-mo | -23.16% |
| 3-mo | -20.65% |
| 6-mo | -26.26% |
| 1-year | -53.50% |
| 3-year | -94.73% |
| 5-year | -96.04% |
| YTD | -36.24% |
| 2023 | -55.19% |
| 2022 | -83.57% |
| 2021 | 17.36% |
| 2020 | 54.07% |
| 2019 | -5.49% |
Continue Researching CKPT
Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...